Antifungal activity of statins and their interaction with amphotericin B against clinically important Zygomycetes

Acta Biologica Hungarica

Volumn 61, Issue 3, 2010, Pages 356-365

  Galgoczy L ^a   Lukács, Gyöngyi ^a   Nyilasi, Ildikó ^a   Papp, T ^a   Vagvolgyi Cs ^a  

^a UNIVERSITY OF SZEGED   (Hungary)

Author keywords

amphotericin B; drug interaction; Statin; synergism; Zygomycetes

Indexed keywords

AMPHOTERICIN B; ATORVASTATIN; ATORVOX; FLUINDOSTATIN; HYDROLYZED LOVASTATIN; HYDROLYZED SIMVASTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; UNCLASSIFIED DRUG; VASILIP; ANTIFUNGAL AGENT;

ABSIDIA; ANTIFUNGAL ACTIVITY; ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; CONTROLLED STUDY; DRUG POTENTIATION; FUNGUS; FUNGUS GROWTH; FUNGUS ISOLATION; GROWTH INHIBITION; IN VITRO STUDY; NONHUMAN; RHIZOMUCOR; RHIZOPUS; SYNCEPHALASTRUM; ZYGOMYCETES; ANTIFUNGAL RESISTANCE; DRUG EFFECTS; DRUG INTERACTION; HUMAN; ISOLATION AND PURIFICATION; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MUCORALES; PATHOGENICITY; ZYGOMYCOSIS;

ABSIDIA; AMPHOTERICIN B; ANTIFUNGAL AGENTS; DRUG INTERACTIONS; DRUG RESISTANCE, FUNGAL; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MICROBIAL SENSITIVITY TESTS; MUCORALES; RHIZOMUCOR; RHIZOPUS; ZYGOMYCOSIS;

EID: 77956013208     PISSN: 02365383     EISSN: 1588256X     Source Type: Journal    
DOI: 10.1556/ABiol.61.2010.3.11     Document Type: Article

References (38)

1. Almyroudis, N. G., Sutton, D. A., Fothergill, A. W., Rinaldi, M. G., Kusne, S. (2007) In vitro susceptibilities of 217 clinicaLisolates of Zygomycetes to conventional and new antifungal agents. Antimicrob. Agents. Ch. 51, 2587-2590.
2. Bellosta, S., Paoletti, R., Corsini, A. (2004) Safety of statins: Focus on clinical pharmacokinetics and drug interactions. American Heart Association, Circulation 109, III-50-III-57, DOI: 10.1161/01. CIR.0000131519.15067.1f
3. Buemi, M., Floccari, F., Nostro, L., Campo, S., Caccamo, C., Sturiale, A., Aloisi, C., Giacobbe, M. S., Frisina, N. (2007) Statins in the prevention of cardiovascular events in patients with renal failure. Cardiovasc. Haematol. Disord. Drug. Targets 7, 7-13.
4. Chamilos, G., Lewis, R. E., Kontoyiannis, D. P. (2006) Lovastatin has significant activity against Zygomycetes and interacts synergistically with voriconazole. Antimicrob. Agents. Ch. 50, 96-103.
5. Chayakulkeeree, M., Ghannoum, M. A., Perfect, J. R. (2006) Zygomycosis: the re-emerging fungaLinfection. Eur. J. Clin. Microbiol. Infect. Dis. 25, 215-229.
6. Cordle, A., Koenigsknecht-Talboo, J., Wilkinson, B., Limpert, A., Landreth, G. (2005) Mechanism of statin-mediated inhibition of small G-protein function. J. Biol. Chem. 280, 34202-34209.
7. Corsini, A., Bellosta, S., Baetta, R., Fumagallia, R., Paolettia, R., Berninib, F. (1999) New insights into the pharmacodynamic and pharmacokinetic properties of statins. Pharmacolo. Therapeut. 84, 413-428.
8. C orsini, A., Bellosta, A., Davidson, H. M. (2005) Pharmacokinetic interactions between statins and fibrates. Am. J. Cardiol. 96, 44-49.
9. Eliopoulos, G. M., Moellering, R. C. (1996) Antimicrobial combinations. In: Lorian, V. (ed.) Antibiotics in Laboratory Medicine. 4th edn. Williams and Wilkins, Baltimore, MD, pp. 330-396.
10. Galgóczy, L., Papp, T., Lukács, Gy., Leiter, É., Pócsi, I., Vágvölgyi, Cs. (2007) Interactions between statins and Penicillium chrysogenum antifungal protein (PAF) to inhibit the germination of sporangiospores of different sensitive Zygomycetes. FEMS Microbiol. Lett. 270, 109-115.
11. Galgóczy, L., Papp, T., Vágvölgyi, Cs. (2009) In vitro interaction between suramin and fluvastatin against clinically important Zygomycetes. Mycoses. 52, 447-453.
12. Gallagher, C. G., Ashley, E. S. D., Drew, R. H., Perfect, J. R. (2003) Antifungal pharmacotherapy for invasive mould infections. Expt. Opin. Pharmacother. 4, 147-164.
13. Ghittoni, R., Patrussi, L., Pirozzi, K., Pellegrini, M., Lazzerini, P. E., Capecchi, P. L., Pasini, F. L., Baldari, C. T. (2005) Simvastatin inhibits T cell activation by selectively impairing the function of Ras superfamily GTPases. The FASEB Journal 19, 605-607.
14. G roll, A. H., Giri, N., Petraitis, V., Petraitiene, R., Candelario, M., Bacher, J. S., Piscitelli, S. C, Walsh, T. J. (2000) Comparative efficacy and distribution of lipid formulations of amphotericin B in experimental Candida albicans. J. Infect. Dis. 182, 274-282.
15. Kajinami, K., Takekoshi, N., Saito, Y. (2003) Pitavastatin: Efficacy and safety profiles of a novel synthetic HMG-CoA reductase inhibitor. Cardiovasc. Drug. Rev. 21, 199-215.
16. Larabi, M., Pages, N., Pons, F., Appel, M., Gulik, A., Schlatter, J., Bouvet, S., Barratt, G. (2004) Study of the toxicity of a new lipid complex formulation of amphotericin B. J. Antimicrob. Chemoth. 53, 81-88.
17. Liao, J. K. (2002) Isoprenoids as mediators of the biological effects of statins. J. Clin. Invest. 110, 285-288.
18. Liao, J. K., Laufs, U. (2005) Pleiotropic effects of statins. Annu. Rev. Pharmacol. Toxicol. 45, 89-118.
19. L orenz, R. T., Parks, L. W. (1990) Effects of Lovastatin (Mevinolin) on sterol levels and on activity of azoles in Saccharomyces cerevisiae. Antimicrob. Agents Chemother. 34, 1660-1665.
20. L ukács, Gy., Papp, T., Nyilasi, I., Nagy, E., Vágvölgyi, Cs. (2004) Differentiation of Rhizomucor species on the basis of their different sensitivities to lovastatin. J. Clin. Microbiol. 42, 5400-5402.
21. L ukács, Gy., Papp, T., Somogyvári, F., Csernetics, Á., Nyilasi, I., Vágvölgyi, Cs. (2008) Cloning of the Rhizomucor miehei 3-hydroxy-3-methylglutaryl-coenzyme A reductase gene and its heterologous expression in Mucor circinelloides. Anton. Leeuw. Int. J. G. 95, 55-64.
22. M iida, T., Hirayama, S., Nakamura, Y. (2004) Cholesterol-independent effects of statins and new therapeutic strategies: ischemic stroke and dementia. J. Atheroscler. Thromb. 11, 253-264.
23. Minassian, B., Huczko, E., Washo, T., Bonner, T., Fung-Tomc, J. (2003) In vitro activity of ravuconazole against Zygomycetes, Scedosporium and Fusarium isolates. Clin. Microbiol. Infect. 9, 1250-1252.
24. Moreno, A. B., del Pozo, A. M., Borja, M., San Segudo, B. (2003) Activity of the antifungal protein from Aspergillus giganteus against Botrytis cinerea. Phytopathology 93, 1344-1353.
25. N ational Committee for Clinical Laboratory Standards. Reference method for broth dilution antifungal susceptibility testing of filamentous fungi. Approved standard. (2002) NCCLS document M38-A. NCCLS, Wayne, Pennsylvania, USA.
26. Nucci, M. (2003) Emerging moulds: Fusarium, Scedosporium and Zygomycetes in transplant recipients. Curr. Opin. Infect. Dis. 16, 607-612.
27. Prabhu, R. M., Patel, R. (2004) Mucormycosis and entomophthoramycosis: a review of the clinical manifestations, diagnosis and treatment. Clin. Microbiol. Infect. 10 (S1), 31-47.
28. R ibes, J. A., Vanhover-Sams, C. L., Baker, D. J. (2000) Zygomycetes in human disease. Clin. Microbiol. Rev. 13, 236-301.
29. R odriguez-Tudela, J. L., Arendrup, M. C., Arikan, S., Barchiesi, F., Bille, J., Chryssanthou, E., Cuenca-Estrella, M., Dannaoui, E., Denning, D. W., Donnelly, J. P., Fegeler, W., Lass-Flörl, C., Moore, C., Richardson, M., Gaustad, P., Schmalreck, A., Velegraki, A., Verweij, P. (2007) Method for the determination of broth dilution minimum inhibitory concentrations of antifungal agents for conidia forming moulds. EUCAST Discussion Document. European Committee on Antimicrobial Susceptibility Testing, Basel, Switzerland.
30. Rogers, T. R. (2008) Treatment of zygomycosis: current and new options. J. Antimicrob. Chemoth. 61(S1), 35-39.
31. Roze, L. V., Linz. J. E. (1998) Lovastatin triggers an apoptosis-like cell death process in the fungus Mucor racemosus. Fungal. Genet. Biol. 25, 119-133.
32. Sabatelli, F., Patel, R., Mann, P. A., Mendrick, C. A., Norris, C. C., Hare, R., Loebenberg, D., Black, T. A., McNicholas, P. M. (2006) In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts. Antimicrob. Agents Ch. 50, 2009-2015.
33. Schachter, M. (2004) Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update. Fund. Clin. Pharmacol. 19, 117-125.
34. Sun, H.-Y., Singh, N. (2009) Antimicrobial and immunomodulatory attributes of statins: Relevance in solid-organ transplant recipients. Clin. Infect. Dis. 48, 745-755.
35. Takó, M., Csernetics, Á. (2005) Genotypic analysis of variability in zygomycetes. Acta Biol. Hung. 56, 345-357.
36. Vazquez, J. A. (2007) Combination antifungal therapy: the new frontier. Future Microbiol. 2, 115-139.
37. Vicente, M. F., Basilio, A., Cabello, A., Pelaez, F. (2003) Microbial natural products as a source of antifungals. Clin. Microbiol. Infect. 9, 15-32.
38. Walsh, T. J., Groll, A., Hiemenz, J., Fleming, R., Roilides, E., Anaissie, E. (2004) Infections due to emerging and uncommon medically important fungal pathogens. Clin. Microbiol. Infect. 10(S1), 48-66.